Masataka Kuwana

1993–2025 年に発表

206
論文数
22,112
被引用数
89
h 指数
190
i10 指数

被引用数

Masataka Kuwana の年別被引用数1993 年: 被引用 2 件1994 年: 被引用 4 件1995 年: 被引用 8 件1996 年: 被引用 13 件1997 年: 被引用 1 件1998 年: 被引用 12 件1999 年: 被引用 8 件2000 年: 被引用 17 件2001 年: 被引用 20 件2002 年: 被引用 25 件2003 年: 被引用 64 件2004 年: 被引用 45 件2005 年: 被引用 69 件2006 年: 被引用 71 件2007 年: 被引用 96 件2008 年: 被引用 92 件2009 年: 被引用 70 件2010 年: 被引用 97 件2011 年: 被引用 120 件2012 年: 被引用 108 件2013 年: 被引用 108 件2014 年: 被引用 147 件2015 年: 被引用 118 件2016 年: 被引用 131 件2017 年: 被引用 132 件2018 年: 被引用 167 件2019 年: 被引用 650 件2020 年: 被引用 785 件2021 年: 被引用 888 件2022 年: 被引用 839 件2023 年: 被引用 546 件2024 年: 被引用 887 件2025 年: 被引用 381 件2026 年: 被引用 7 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,431 件、この内訳の 19.3%日本: 引用元論文 683 件、この内訳の 9.2%イタリア: 引用元論文 589 件、この内訳の 8%中国: 引用元論文 562 件、この内訳の 7.6%イギリス: 引用元論文 532 件、この内訳の 7.2%ドイツ: 引用元論文 430 件、この内訳の 5.8%フランス: 引用元論文 426 件、この内訳の 5.8%カナダ: 引用元論文 252 件、この内訳の 3.4%スイス: 引用元論文 217 件、この内訳の 2.9%オランダ: 引用元論文 198 件、この内訳の 2.7%スペイン: 引用元論文 195 件、この内訳の 2.6%オーストラリア: 引用元論文 144 件、この内訳の 1.9%
0%19.3%その他 23.6%

分野

  • Medicine90.2%
  • Immunology and Microbiology4.6%
  • Biochemistry, Genetics and Molecular Biology3.9%
  • Neuroscience0.3%
  • Engineering0.2%
  • Materials Science0.2%
  • その他0.6%

トピック

  • Systemic Sclerosis and Related Diseases12.8%
  • Inflammatory Myopathies and Dermatomyositis11.2%
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis9%
  • Pulmonary Hypertension Research and Treatments2.5%
  • Eosinophilic Disorders and Syndromes2.4%
  • Platelet Disorders and Treatments2.3%
  • その他59.8%

共著者

全論文

検索で開く
  1. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

    著者: , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 1,613

  2. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mette Mogensen, Anne Braae Olesen, Yannick Allanore, J. Henes, Ulf Müller‐Ladner, Gabriela Riemekasten, Alla Skapenko, Panayiotis G. Vlachoyiannopoulos, Emese Kiss, Tünde Minier, Lorenzo Beretta, Elisa Gremese, Marco Matucci‐Cerinic, Gabriele Valentini, Yoshihide Asano, Tatsuya Atsumi, Hironobu Ihn, Tomonori Ishii, Osamu Ishikawa, Masataka Kuwana, Yoshihito Shima, Hiroki Takahashi, Kazuhiko Takehara, Yoshiya Tanaka, Yoshioki Yamasaki, Loreta Bukauskienė, İrena Butrimienė, Gabriel Medrano Ramírez, César Ramos-Remus, Tatiana Sofía Rodríguez Reyna, Jeska de Vries‐Bouwstra, Jacob M. van Laar, Bogdan Batko, Sławomir Jeka, Eugeniusz J. Kucharz, Maria Majdan, Marzena Olesińska, Żaneta Smoleńska, José Delgado Alves, María José Santos, C. Mihai, Simona Rednic, Ivan Castellvi Barranco, Francisco Longo, C Simeόn Aznar, Patrícia Carreira, Oliver Distler, Ulrich A. Walker, Emma Derrett‐Smith, Bridget Griffiths, Neil D McKay, Christopher P. Denton, Jacob Aelion, Michael Borofsky, Roy Fleischmann, Joseph Z. Forstot, Daniel E. Furst, Suzanne Kafaja, Mahmuda Khan, Dinesh Khanna, Michael Kohen, Richard W. Martin, Fabian Mendoza-Ballesteros, Alireza Nami, Shirley Pang, Grissel Ríos, Robert W. Simms, Keith M. Sullivan, Virginia Steen - The Lancet Respiratory Medicine 2020 被引用: 652

  3. Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis

    著者: , , , , , , , , , , , , , , , , , - Journal of Scleroderma and Related Disorders 2017 被引用: 521

  4. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Respiratory Medicine 2021 被引用: 212

  5. Autoantibodies to a 140‐kd polypeptide, CADM‐140, in Japanese patients with clinically amyopathic dermatomyositis

    著者: , , , , , , , , - Arthritis & Rheumatism 2005 被引用: 742

  6. International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mazen M. Dimachkie, Erik Ensrud, Floranne C. Ernste, D. Gareth Evans, Manabu Fujimoto, Ignacio García‐De La Torre, Abraham García-Kutzbach, Zoltán Griger, Latika Gupta, Marie Hudson, Florenzo Iannone, David Isenberg, Joseph L. Jorizzo, Helen Kurtz, Masataka Kuwana, Vidya Limaye, Ingrid E. Lundberg, Andrew L. Mammen, H. Mann, Frank Mastaglia, Lorna McWilliams, Christopher A. Mecoli, Federica Meloni, Frederick W. Miller, Siamak Moghadam‐Kia, Sergey Moiseev, Yoshinao Muro, Melinda Nagy‐Vincze, Clive Nayler, Merrilee Needham, Ichizo Nishino, Chester V. Oddis, Julie J. Paik, Joost Raaphorst, Lisa G. Rider, Jorge Rojas‐Serrano, Lesley Ann Saketkoo, Adam Schiffenbauer, Samuel Katsuyuki Shinjo, Vineeta Shobha, Yeong‐Wook Song, Tania Tillett, Yves Troyanov, Anneke J. van der Kooi, Mónica Vázquez-Del Mercado, Jiří Vencovský, Qian Wang, Steven R. Ytterberg, Rohit Aggarwal - Nature Reviews Rheumatology 2023 被引用: 139

  7. Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nobuhiro Tanabe, Ichizo Tsujino, Atsushi Yao, Takashi Akasaka, Motomi Ando, Takeshi Kimura, Takayuki Kuriyama, Norifumi Nakanishi, Toshio Nakanishi, Hiroyuki Tsutsui, on behalf of the Japanese Circulation Society and the Japanese Pulmonary Circulation and Pulmonary Hypertension Society Joint Working Group - Circulation Journal 2019 被引用: 222

  8. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM

    著者: , , , , , , , , , , , , , , , , , , , , , - Lara D. Veeken 2012 被引用: 317

  9. Utility of Anti–Melanoma Differentiation–Associated Gene 5 Antibody Measurement in Identifying Patients With Dermatomyositis and a High Risk for Developing Rapidly Progressive Interstitial Lung Disease: A Review of the Literature and a Meta‐Analysis

    著者: , , , , , , - Arthritis Care & Research 2013 被引用: 293

  10. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis

    著者: , , , , , , , , , , - Lara D. Veeken 2012 被引用: 337

  11. Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas Krieg, R Marcolongo, Ilaria Galetti, Elisabetta Zanatta, Francesco Tona, Petar Seferović, Marco Matucci‐Cerinic - Journal of Scleroderma and Related Disorders 2021 被引用: 75

  12. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Susumu Sakamoto, Shinji Sato, Toshimasa Shimizu, Noboru Takayanagi, Reoto Takei, Tamiko Takemura, Tohru Takeuchi, Yuko Toyoda, Hidehiro Yamada, Hideaki Yamakawa, Yasuhiko Yamano, Yoshioki Yamasaki, Masataka Kuwana - Respiratory Investigation 2021 被引用: 108

  13. Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit

    著者: , , , , , , - Current Opinion in Rheumatology 2022 被引用: 57

  14. Anti–Melanoma Differentiation–Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis

    著者: , , , , - Arthritis Care & Research 2015 被引用: 285

  15. Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis–Associated Interstitial Lung Disease

    著者: , , , , , , , , , , , , , , , , , - Arthritis & Rheumatology 2020 被引用: 138

  16. RNA helicase encoded by melanoma differentiation–associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease

    著者: , , , , , , - Arthritis & Rheumatism 2009 被引用: 600

  17. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis

    著者: , , , , , , , , , , , - Lara D. Veeken 2010 被引用: 327

  18. Consensus on the assessment of systemic sclerosis–associated primary heart involvement: World Scleroderma Foundation/Heart Failure Association guidance on screening, diagnosis, and follow-up assessment

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alessia Pepe, Oliver Distler, Petros P. Sfikakis, Petar Seferović, Marco Matucci‐Cerinic - Journal of Scleroderma and Related Disorders 2023 被引用: 56

  19. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities

    著者: , , - Journal of Scleroderma and Related Disorders 2017 被引用: 324

  20. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2020 被引用: 107

  21. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher P. Denton, the RESOLVE‐1 Study Group - Arthritis & Rheumatology 2023 被引用: 43

  22. The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis

    著者: , , , , , , , - Arthritis Research & Therapy 2020 被引用: 60

  23. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease

    著者: , , , , , , , , , , , - Lara D. Veeken 2014 被引用: 188

  24. Sarcoplasmic MxA expression

    著者: , , , , , , , , - Neurology 2016 被引用: 162